{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:49:23Z","timestamp":1789544963474,"version":"build-2803163510"},"reference-count":74,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"BeiGene USA"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ibrutinib is a first-generation inhibitor of Bruton tyrosine kinase (BTK) that is currently approved to treat patients with B-cell malignancies, including Waldenstr\u00f6m macroglobulinemia (WM), relapsed\/refractory (R\/R) mantle cell lymphoma (MCL), R\/R marginal zone lymphoma (MZL), and chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL). Off-target adverse effects, such as atrial fibrillation, hypertension, and bleeding, have been observed and may limit a patient\u2019s tolerance for treatment. Currently, there is no well-established treatment regimen for patients who cannot tolerate ibrutinib. Approaches to address such patients include managing ibrutinib side effects with supportive care or dose reductions, switching to an alternative covalent BTK inhibitor, or abandoning covalent BTK inhibitors for alternative forms of treatment. Here we review the literature and provide guidance on treating ibrutinib-intolerant patients with B-cell malignancies.<\/jats:p>","DOI":"10.1093\/oncolo\/oyac260","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:33:28Z","timestamp":1675298008000},"page":"309-318","source":"Crossref","is-referenced-by-count":11,"title":["Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies"],"prefix":"10.1093","volume":"28","author":[{"given":"Javier","family":"Mu\u00f1oz","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Mayo Clinic, Phoenix, AZ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayna","family":"Sarosiek","sequence":"additional","affiliation":[{"name":"Bing Center for Waldenstr\u00f6m Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9490-7532","authenticated-orcid":false,"given":"Jorge J","family":"Castillo","sequence":"additional","affiliation":[{"name":"Bing Center for Waldenstr\u00f6m Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,2,1]]},"reference":[{"issue":"4","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton\u2019s tyrosine kinase in B cell malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat Rev Cancer."},{"issue":"1","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton\u2019s tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol Cancer."},{"key":"2023041314291469500_","volume-title":"Imbruvica (ibrutinib) [package insert]","year":"2019"},{"issue":"11","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1016\/S2352-3026(20)30224-6","article-title":"Consensus treatment recommendations from the tenth International Workshop for Waldenstr\u00f6m Macroglobulinaemia","volume":"7","author":"Castillo","year":"2020","journal-title":"Lancet Haematol."},{"key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.3389\/fonc.2020.01712","article-title":"Trends in incidence and mortality of Waldenstr\u00f6m macroglobulinemia: a population-based study","volume":"10","author":"Yin","year":"2020","journal-title":"Front Oncol."},{"issue":"1","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/ajh.23351","article-title":"Patterns of survival in lymphoplasmacytic lymphoma\/Waldenstr\u00f6m macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005","volume":"88","author":"Kristinsson","year":"2013","journal-title":"Am J Hematol."},{"issue":"1","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.pathol.2019.09.009","article-title":"Lymphoplasmacytic lymphoma and Waldenstr\u00f6m macroglobulinaemia: clinicopathological features and differential diagnosis","volume":"52","author":"Wang","year":"2020","journal-title":"Pathology."},{"issue":"1","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13045-020-00914-1","article-title":"Emerging therapies in mantle cell lymphoma","volume":"13","author":"Hanel","year":"2020","journal-title":"J Hematol Oncol."},{"key":"2023041314291469500_","volume-title":"Mantle Cell Lymphoma Facts"},{"key":"2023041314291469500_","volume-title":"Mantle Cell Lymphoma","author":"Lynch","year":"2022"},{"issue":"1","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","article-title":"Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Zucca","year":"2020","journal-title":"Ann Oncol."},{"key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/aol-20-28","article-title":"Epidemiology of marginal zone lymphoma","volume":"5","author":"Cerhan","year":"2021","journal-title":"Ann Lymphoma."},{"issue":"12","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s11864-019-0687-5","article-title":"Marginal zone lymphoma: state-of-the-art treatment","volume":"20","author":"Sindel","year":"2019","journal-title":"Curr Treat Options Oncol."},{"issue":"3","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"326","DOI":"10.6004\/jnccn.2015.0045","article-title":"Chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 1.2015","volume":"13","author":"Zelenetz","year":"2015","journal-title":"J Natl Compr Canc Netw."},{"issue":"11","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am J Hematol."},{"issue":"5","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/14737140.2022.2064849","article-title":"Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia","volume":"22","author":"Sarosiek","year":"2022","journal-title":"Expert Rev Anticancer Ther."},{"key":"2023041314291469500_","volume-title":"Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (Version 1.2023)","author":"National Comprehensive Cancer Network."},{"key":"2023041314291469500_","volume-title":"Waldenstr\u00f6m Macroglobulinemia\/Lymphoplasmacytic Lymphoma (Version 1.2023)","author":"National Comprehensive Cancer Network."},{"key":"2023041314291469500_","volume-title":"B-Cell Lymphomas (Version 5.2022)","author":"National Comprehensive Cancer Network."},{"issue":"15","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med."},{"issue":"2","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41375-021-01417-9","article-title":"Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia","volume":"36","author":"Castillo","year":"2022","journal-title":"Leukemia."},{"issue":"6","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.20.00555","article-title":"Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenstr\u00f6m macroglobulinemia","volume":"39","author":"Treon","year":"2021","journal-title":"J Clin Oncol."},{"issue":"25","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 trial of ibrutinib plus rituximab in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med."},{"issue":"1","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.21.00838","article-title":"Ibrutinib plus rituximab versus placebo plus rituximab for Waldenstr\u00f6m\u2019s macroglobulinemia: final analysis from the randomized Phase III iNNOVATE study","volume":"40","author":"Buske","year":"2022","journal-title":"J Clin Oncol."},{"issue":"6","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med."},{"issue":"16","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood."},{"issue":"12","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol."},{"issue":"11","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv."},{"issue":"13","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1080\/10428194.2020.1795159","article-title":"Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"61","author":"Fraser","year":"2020","journal-title":"Leuk Lymphoma."},{"issue":"35","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.2217\/fon-2021-0964","article-title":"Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia","volume":"17","author":"Hou","year":"2021","journal-title":"Future Oncol."},{"issue":"10","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1002\/cam4.2998","article-title":"The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice","volume":"9","author":"Parikh","year":"2020","journal-title":"Cancer Med."},{"issue":"Supplement 1","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1182\/blood-2021-154284","article-title":"Dose reductions related to adverse effects in patients with Waldenstr\u00f6m macroglobulinemia treated with the BTK-inhibitor ibrutinib","volume":"138","author":"Sarosiek","year":"2021","journal-title":"Blood."},{"issue":"4","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"e00156","DOI":"10.1002\/prp2.156","article-title":"Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants","volume":"3","author":"de Jong","year":"2015","journal-title":"Pharmacol Res Perspect."},{"issue":"4","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ajh.25023","article-title":"Ibrutinib discontinuation in Waldenstr\u00f6m macroglobulinemia: etiologies, outcomes, and IgM rebound","volume":"93","author":"Gustine","year":"2018","journal-title":"Am J Hematol."},{"issue":"10","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica."},{"key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.critrevonc.2019.02.001","article-title":"Management of adverse effects\/toxicity of ibrutinib","volume":"136","author":"Paydas","year":"2019","journal-title":"Crit Rev Oncol Hematol."},{"issue":"12","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood-2018-11-846808","article-title":"How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia","volume":"133","author":"Stephens","year":"2019","journal-title":"Blood."},{"issue":"12","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3324\/haematol.2015.126672","article-title":"Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"100","author":"Lipsky","year":"2015","journal-title":"Haematologica."},{"issue":"6","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood."},{"issue":"16","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood."},{"issue":"1","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/bjh.14302","article-title":"Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management","volume":"180","author":"Iberri","year":"2018","journal-title":"Br J Haematol."},{"issue":"4","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4049\/jimmunol.1500861","article-title":"G-CSF and GM-CSF in Neutropenia","volume":"195","author":"Mehta","year":"2015","journal-title":"J Immunol."},{"issue":"4","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2017-08-764712","article-title":"How I treat CLL patients with ibrutinib","volume":"131","author":"Brown","year":"2018","journal-title":"Blood."},{"issue":"1","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med."},{"issue":"1","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol."},{"key":"2023041314291469500_","volume-title":"Calquence (acalabrutinib) [package insert]","year":"2019"},{"issue":"31","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol."},{"issue":"2","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/S2352-3026(19)30210-8","article-title":"Acalabrutinib monotherapy in patients with Waldenstr\u00f6m macroglobulinemia: a single-arm, multicentre, phase 2 study","volume":"7","author":"Owen","year":"2020","journal-title":"Lancet Haematol."},{"issue":"1","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.18368","article-title":"A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma","volume":"199","author":"Strati","year":"2022","journal-title":"Br J Haematol."},{"issue":"9","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/bloodadvances.2018030007","article-title":"Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib","volume":"3","author":"Awan","year":"2019","journal-title":"Blood Adv."},{"issue":"9","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.3324\/haematol.2020.272500","article-title":"Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"106","author":"Rogers","year":"2021","journal-title":"Haematologica."},{"key":"2023041314291469500_","volume-title":"Brukinsa (zanubrutinib) [package insert]","year":"2021"},{"issue":"18","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood.2020006449","article-title":"Zanubrutinib for the treatment of patients with Waldenstr\u00f6m macroglobulinemia: 3 years of follow-up","volume":"136","author":"Trotman","year":"2020","journal-title":"Blood."},{"issue":"11","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood."},{"issue":"12","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1182\/bloodadvances.2020004074","article-title":"Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma","volume":"5","author":"Tam","year":"2021","journal-title":"Blood Adv."},{"key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/20406207221093980","article-title":"Zanubrutinib in lymphoproliferative disorders: a comprehensive review","volume":"13","author":"Mu\u00f1oz","year":"2022","journal-title":"Ther Adv Hematol."},{"issue":"4","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1182\/bloodadvances.2021005621","article-title":"Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies","volume":"6","author":"Tam","year":"2021","journal-title":"Blood Adv."},{"key":"2023041314291469500_","volume-title":"First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma [Abstract]","author":"Hillmen","year":"2021"},{"issue":"22","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.2217\/fon-2018-0163","article-title":"A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenstr\u00f6m macroglobulinemia","volume":"14","author":"Tam","year":"2018","journal-title":"Future Oncol."},{"issue":"18","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood."},{"issue":"Supplement 1","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2021-148544","article-title":"Phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients (Pts) with relapsed\/refractory B-Cell malignancies","volume":"138","author":"Shadman","year":"2021","journal-title":"Blood."},{"issue":"4","key":"2023041314291469500_","first-page":"390","article-title":"Cost-effectiveness and value of information analyses of Bruton\u2019s tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States","volume":"28","author":"Alrawashdh","year":"2022","journal-title":"J Manag Care Spec Pharm."},{"issue":"15_suppl","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"e18856","DOI":"10.1200\/JCO.2021.39.15_suppl.e18856","article-title":"Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenstr\u00f6m macroglobulinemia in the United States","volume":"39","author":"Castillo","year":"2021","journal-title":"J Clin Oncol."},{"issue":"17","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood.2020004922","article-title":"Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia","volume":"136","author":"Patel","year":"2020","journal-title":"Blood."},{"issue":"26","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1200\/JCO.2010.33.8061","article-title":"Bendamustine combined with rituximab in patients with relapsed and\/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"29","author":"Fischer","year":"2011","journal-title":"J Clin Oncol."},{"issue":"3","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2141.2011.08597.x","article-title":"Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study","volume":"153","author":"Iannitto","year":"2011","journal-title":"Br J Haematol."},{"issue":"7","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3324\/haematol.2011.041392","article-title":"Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma","volume":"96","author":"Lamm","year":"2011","journal-title":"Haematologica."},{"issue":"5","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.3324\/haematol.2021.279112","article-title":"Natural history of Waldenstr\u00f6m macroglobulinemia following acquired resistance to ibrutinib monotherapy","volume":"107","author":"Gustine","year":"2022","journal-title":"Haematologica."},{"key":"2023041314291469500_","volume-title":"Venclexta (venetoclax) [package insert]","year":"2020"},{"issue":"17","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-20-4842","article-title":"Long-term follow-up of patients with relapsed or refractory non-hodgkin lymphoma treated with venetoclax in a phase I, first-in-human study","volume":"27","author":"Davids","year":"2021","journal-title":"Clin Cancer Res."},{"key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"100527","DOI":"10.1016\/j.ctarc.2022.100527","article-title":"Current approach to Waldenstr\u00f6m Macroglobulinemia","volume":"31","author":"Ravi","year":"2022","journal-title":"Cancer Treat Res Commun."},{"issue":"1","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.21.01194","article-title":"Venetoclax in previously treated Waldenstr\u00f6m macroglobulinemia","volume":"40","author":"Castillo","year":"2021","journal-title":"J Clin Oncol."},{"issue":"10277","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet."},{"issue":"3","key":"2023041314291469500_","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3390\/cancers14030771","article-title":"The role of Bruton\u2019s kinase inhibitors in chronic lymphocytic leukemia: current status and future directions","volume":"14","author":"Robak","year":"2022","journal-title":"Cancers (Basel)."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/4\/309\/49880499\/oyac260.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/4\/309\/49880499\/oyac260.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T16:57:54Z","timestamp":1701536274000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/4\/309\/7022099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":74,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2,1]]},"published-print":{"date-parts":[[2023,4,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac260","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2023,2,1]]}}}